Predictive value of the Luminex single antigen panel for detecting flow cytometry cross-match positivity

Human Immunology

Volumn 73, Issue 5, 2012, Pages 517-521

  Moreno, Cristina ^a   Burgos, Leire ^a   Pérez Robles, Carmen ^a   Delgado, Jose A ^a   Mata, Juan J ^a   Errasti, Pedro ^a   Martín, Paloma ^a   Merino, Juana ^a   Sánchez Ibarrola, Alfonso ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Anti HLA antibody; Flow cytometry; Luminex; Solid phase assay; Virtual cross match

Indexed keywords

HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CROSS REACTION; FLOW CYTOMETRY; FLOW CYTOMETRY CROSSMATCHING; FLUORESCENCE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; TRANSPLANTATION;

CROSS REACTIONS; FLOW CYTOMETRY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOASSAY; ISOANTIBODIES; PREDICTIVE VALUE OF TESTS;

EID: 84863418509     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2012.02.022     Document Type: Article

References (30)

1. Patel R., Terasaki P.I. Significance of the positive cross-match test in kidney transplantation. N Engl J Med 1969, 280:735-739.
2. Opelz G., Döhler B., Süsal C. Analysis of positive kidney, heart, and liver transplant cross-matches reported to the Collaborative Transplant Study. Hum Immunol 2009, 70:627-630.
3. Lefaucheur C., Suberbielle-Boissel C., Hill G.S., Nochy D., Andrade J., Antoine C., et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008, 8:324-331.
4. Kraus E.S., Parekh R.S., Oberai P., Lepley D., Segev D.L., Bagnasco S., et al. Subclinical rejection in stable positive cross-match kidney transplant patients: incidence and correlations. Am J Transplant 2009, 9:1826-1834.
5. Böhmig G.A., Bartel G., Regele H., Wahrmann M. Prospects and limitations of post-transplantation alloantibody detection in renal transplantation. Hum Immunol 2009, 70:640-644.
6. Colvin R.B. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007, 18:1046-1056.
7. Karpinski M., Rush D., Jeffery J., Exner M., Regele H., Dancea S., et al. Flow cytometric cross-matching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity cross-match. J Am Soc Nephrol 2001, 12:2807-2814.
8. Bryan C.F., Baier K.A., Nelson P.W., Luger A.M., Martinez J., Pierce G.E., et al. Long-term graft survival is improved in cadaveric renal retransplantation by flow cytometric cross-matching. Transplantation 1998, 66:1827-1832.
9. Bray R.A., Nickerson P.W., Kerman R.H., Gebel H.M. Evolution of HLA antibody detection: technology emulating biology. Immunol Res 2004, 29:41-54.
10. Gupta A., Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a risk factor. Hum Immunol 2009, 70:618-622.
11. Amico P., Hönger G., Mayr M., Steiger J., Hopfer H., Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009, 87:1681-1688.
12. Zeevi A., Girnita A., Duquesnoy R. HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation. Immunol Res 2006, 36:255-264.
13. Bray R.A., Gebel H.M. Strategies for human leukocyte antigen antibody detection. Curr Opin Organ Transplant 2009, 14:392-397.
14. Amico P., Hönger G., Steiger J., Schaub S. Utility of the virtual cross-match in solid organ transplantation. Curr Opin Organ Transplant 2009, 14:656-661.
15. Bielmann D., Hönger G., Lutz D., Mihatsch M.J., Steiger J., Schaub S. Pretransplant risk assessment in renal allograft recipients using virtual cross-matching. Am J Transplant 2007, 7:626-632.
16. Taylor C.J., Kosmoliaptsis V., Summers D.M., Bradley J.A. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol 2009, 70:563-568.
17. Tait B.D., Hudson F., Brewin G., Cantwell L., Holdsworth R. Solid phase HLA antibody detection technology-challenges in interpretation. Tissue Antigens 2010, 76:87-95.
18. Morales-Buenrostro L.E., Terasaki P.I., Marino-Vázquez L.A., Lee J.H., El-Awar N., Alberú J. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008, 86:1111-1115.
19. Zachary A.A., Sholander J.T., Houp J.A., Leffell M.S. Using real data for a virtual cross-match. Hum Immunol 2009, 70:574-579.
20. Batal I., Zeevi A., Lunz J.G., Aggarwal N., Shapiro R., Randhawa P., et al. Antihuman leukocyte antigen-specific antibody strength determined by complement-dependent or solid-phase assays can predict positive donor-specific cross-matches. Arch Pathol Lab Med 2010, 134:1534-1540.
21. Reinsmoen N.L., Lai C.H., Vo A., Cao K., Ong G., Naim M., et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008, 86:820-825.
22. Tambur A.R., Ramon D.S., Kaufman D.B., Friedewald J., Luo X., Ho B., et al. Perception versus reality?: virtual cross-match-how to overcome some of the technical and logistic limitations. Am J Transplant 2009, 9:1886-1893.
23. Morris G.P., Phelan D.L., Jendrisak M.D., Mohanakumar T. Virtual cross-match by identification of donor-specific anti-human leukocyte antigen antibodies by solid-phase immunoassay: a 30-month analysis in living donor kidney transplantation. Hum Immunol 2010, 71:268-273.
24. Nikaein A., Cherikh W., Nelson K., Baker T., Leffell S., Bow L., et al. Organ Procurement and Transplantation Network/United Network for Organ Sharing Histocompatibility Committee collaborative study to evaluate prediction of cross-match results in highly sensitized patients. Transplantation 2009, 87:557-562.
25. Graff R.J., Buchanan P.M., Dzebisashvili N., Schnitzler M.A., Tuttle-Newhall J., Xiao H., et al. The clinical importance of flow cytometry cross-match in the context of CDC cross-match results. Transplant Proc 2010, 42:3471-3474.
26. Ho E.K., Vasilescu E.R., Colovai A.I., Stokes M.B., Hallar M., Markowitz G.S., et al. Sensitivity, specificity and clinical relevance of different cross-matching assays in deceased-donor renal transplantation. Transpl Immunol 2008, 20:61-67.
27. Aubert V., Venetz J.P., Pantaleo G., Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol 2009, 70:580-583.
28. Süsal C., Ovens J., Mahmoud K., Döhler B., Scherer S., Ruhenstroth A., et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a collaborative transplant study report. Transplantation 2011, 91:883-887.
29. Jindra P.T., Jin Y.P., Rozengurt E., Reed E.F. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008, 180:2357-2366.
30. Jindra P.T., Zhang X., Mulder A., Claas F., Veale J., Jin Y.P., et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006, 82(suppl 1):33-35.